Association of Liver Stiffness with Hepatic Expression of Pharmacokinetically Important Genes in Alcoholic Liver Disease

Alcoholism: Clinical and Experimental Research

Volumn 37, Issue SUPPL.1, 2013, Pages

  Theile, Dirk ^a   Haefeli, Walter Emil ^a   Seitz, Helmut Karl ^a   Millonig, Gunda ^a   Weiss, Johanna ^a   Mueller, Sebastian ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Alcohol; Drug metabolism; Drug transporters; Fibroscan; Liver stiffness

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; DRUG METABOLIZING ENZYME; MESSENGER RNA; ORGANIC ANION TRANSPORTER 2;

ADULT; ALCOHOL LIVER DISEASE; ALCOHOLISM; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ELASTOGRAPHY; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; LIVER DISEASE; LIVER STIFFNESS; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS;

ADULT; CYTOCHROME P-450 ENZYME SYSTEM; ELASTICITY IMAGING TECHNIQUES; FEMALE; GENE EXPRESSION REGULATION; HUMANS; LIVER; LIVER CIRRHOSIS; LIVER DISEASES, ALCOHOLIC; MALE; MIDDLE AGED; ORGANIC ANION TRANSPORTERS; RNA, MESSENGER;

EID: 84872485653     PISSN: 01456008     EISSN: 15300277     Source Type: Journal    
DOI: 10.1111/j.1530-0277.2012.01901.x     Document Type: Article

References (49)

1. Abdel-Razzak Z, Loyer P, Fautrel A, Gautier JC, Corcos L, Turlin B, Beaune P, Guillouzo A (1993) Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture. Mol Pharmacol 44:707-715.
2. Barreiro P, Rodríguez-Novoa S, Labarga P, Ruiz A, Jiménez-Nácher I, Martín-Carbonero L, Gonzalez-Lahoz J, Soriano V (2007) Influence of liver fibrosis stage on plasma levels of antiretroviral drugs in HIV-infected patients with chronic hepatitis C. J Infect Dis 195:973-979.
3. Bogan I, Smith H (1967) Analytical investigation of barbiturate poisoning-description of methods and a survey of results. J Forensic Sci 7:37-45.
4. Castera L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, Darriet M, Couzigou P, De Ledinghen V (2005) Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 128:343-350.
5. Ciraulo DA, Barnhill JG, Jaffe JH (1988) Clinical pharmacokinetics of imipramine and desipramine in alcoholics and normal volunteers. Clin Pharmacol Ther 43:509-518.
6. Couderc E, Ferrier C, Haberer JP, Henzel D, Duvaldestin P (1984) Thiopentone pharmacokinetics in patients with chronic alcoholism. Br J Anaesth 56:1393-1397.
7. Denaro CP, Wilson M, Jacob P 3rd, Benowitz NL (1996) The effect of liver disease on urine caffeine metabolite ratios. Clin Pharmacol Ther 59:624-635.
8. Dilger K, Metzler J, Bode JC, Klotz U (1997) CYP2E1 activity in patients with alcoholic liver disease. J Hepatol 27:1009-1014.
9. Fardel O, Le Vée M (2009) Regulation of human hepatic drug transporter expression by pro-inflammatory cytokines. Expert Opin Drug Metab Toxicol 5:1469-1481.
10. Feierman DE, Melinkov Z, Nanji AA (2003) Induction of CYP3A by ethanol in multiple in vitro and in vivo models. Alcohol Clin Exp Res 27:981-988.
11. Forestier J, Dumortier J, Guillaud O, Ecochard M, Roman S, Boillot O, Lutringer D, Scoazec JY, Subtil F, Mion F (2010) Noninvasive diagnosis and prognosis of liver cirrhosis: a comparison of biological scores, elastometry, and metabolic liver function tests. Eur J Gastroenterol Hepatol 22:532-540.
12. Girre C, Lucas D, Hispard E, Menez C, Dally S, Menez JF (1994) Assessment of cytochrome P4502E1 induction in alcoholic patients by chlorzoxazone pharmacokinetics. Biochem Pharmacol 47:1503-1508.
13. Greenberg DM, Lee JW (2001) Psychotic manifestations of alcoholism. Curr Psychiatry Rep 3:314-318.
14. Gyamfi MA, Wan YJ (2010) Pathogenesis of alcoholic liver disease: the role of nuclear receptors. Exp Biol Med (Maywood) 235:547-560.
15. Hanada K, Nakai K, Tanaka H, Suzuki F, Kumada H, Ohno Y, Ozawa S, Ogata H (2011) Effect of nuclear receptor downregulation on hepatic expression of cytochrome P450 and transporters in chronic hepatitis C in association with fibrosis development. Drug Metab Pharmacokinet 27:301-306.
16. Ho RH, Kim RB (2005) Transporters and drug therapy: implications for drug disposition and disease. Clin Pharmacol Ther 78:260-277.
17. Hoensch H (1987) Ethanol as enzyme inducer and inhibitor. Pharmacol Ther 33:121-128.
18. Jin M, Arya P, Patel K, Singh B, Silverstein PS, Bhat HK, Kumar A, Kumar S (2011) Effect of alcohol on drug efflux protein and drug metabolic enzymes in U937 macrophages. Alcohol Clin Exp Res 35:132-139.
19. Kato S, Tajiri T, Matsukura N, Matsuda N, Taniai N, Mamada H, Yoshida H, Kiyam T, Naito Z (2003) Genetic polymorphisms of aldehyde dehydrogenase 2, cytochrome p450 2E1 for liver cancer risk in HCV antibody-positive japanese patients and the variations of CYP2E1 mRNA expression levels in the liver due to its polymorphism. Scand J Gastroenterol 38:886-893.
20. Klotz U, Ammon E (1998) Clinical and toxicological consequences of the inductive potential of ethanol. Eur J Clin Pharmacol 54:7-12.
21. König SK, Herzog M, Theile D, Zembruski N, Haefeli WE, Weiss J (2010) Impact of drug transporters on cellular resistance towards saquinavir and darunavir. J Antimicrob Chemother 65:2319-2328.
22. Kostrubsky VE, Strom SC, Wood SG, Wrighton SA, Sinclair PR, Sinclair JF (1995) Ethanol and isopentanol increase CYP3A and CYP2E in primary cultures of human hepatocytes. Arch Biochem Biophys 322:516-520.
23. Le Couteur DG, Fraser R, Hilmer S, Rivory LP, McLean AJ (2005) The hepatic sinusoid in aging and cirrhosis: effects on hepatic substrate disposition and drug clearance. Clin Pharmacokinet 44:187-200.
24. Liangpunsakul S, Kolwankar D, Pinto A, Gorski JC, Hall SD, Chalasani N (2005) Activity of CYP2E1 and CYP3A enzymes in adults with moderate alcohol consumption: a comparison with nonalcoholics. Hepatology 41:1144-1150.
25. Lieber CS (1995) Medical disorders of alcoholism. N Engl J Med 333:1058-1065.
26. Lieber CS (1999) Microsomal ethanol-oxidizing system (MEOS): the first 30 years (1968-1998)-a review. Alcohol Clin Exp Res 23:991-1007.
27. Louis CA, Wood SG, Kostrubsky V, Sinclair PR, Sinclair JF (1994) Synergistic increases in rat hepatic cytochrome P450s by ethanol and isopentanol. J Pharmacol Exp Ther 269:838-845.
28. Meyer Zu Schwabedissen HE, Böttcher K, Chaudhry A, Kroemer HK, Schuetz EG, Kim RB (2010) Liver X receptor α and farnesoid X receptor are major transcriptional regulators of OATP1B1. Hepatology 52:1797-1807.
29. Millonig G, Friedrich S, Adolf S, Fonouni H, Golriz M, Mehrabi A, Stiefel P, Pöschl G, Büchler MW, Seitz HK, Mueller S (2010) Liver stiffness is directly influenced by central venous pressure. J Hepatol 52:206-210.
30. Millonig G, Reimann FM, Friedrich S, Fonouni H, Mehrabi A, Büchler MW, Seitz HK, Mueller S (2008) Extrahepatic cholestasis increases liver stiffness (FibroScan) irrespective of fibrosis. Hepatology 48:1718-1723.
31. Misra PS, Lefévre A, Ishii H, Rubin E, Lieber CS (1971) Increase of ethanol, meprobamate and pentobarbital metabolism after chronic ethanol administration in man and in rats. Am J Med 51:346-351.
32. Morgan ET, Goralski KB, Piquette-Miller M, Renton KW, Robertson GR, Chaluvadi MR, Charles KA, Clarke SJ, Kacevska M, Liddle C, Richardson TA, Sharma R, Sinal CJ (2008) Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer. Drug Metab Dispos 36:205-216.
33. Mueller S, Millonig G, Sarovska L, Friedrich S, Reimann FM, Pritsch M, Eisele S, Stickel F, Longerich T, Schirmacher P, Seitz HK (2010) Increased liver stiffness in alcoholic liver disease: differentiating fibrosis from steatohepatitis. World J Gastroenterol 16:966-972.
34. Mueller S, Sandrin L (2010) Liver stiffness: a novel parameter for the diagnosis of liver disease. Hepat Med 2:49-67.
35. Nakai K, Tanaka H, Hanada K, Ogata H, Suzuki F, Kumada H, Miyajima A, Ishida S, Sunouchi M, Habano W, Kamikawa Y, Kubota K, Kita J, Ozawa S, Ohno Y (2008) Decreased expression of cytochromes P450 1A2, 2E1, and 3A4 and drug transporters Na+-taurocholate-cotransporting polypeptide, organic cation transporter 1, and organic anion-transporting peptide-C correlates with the progression of liver fibrosis in chronic hepatitis C patients. Drug Metab Dispos 36:1786-1793.
36. Naveau S, Perlemuter G, Balian A (2005) Epidemiology and natural history of cirrhosis. Rev Prat 55:1527-1532.
37. Neuvonen PJ, Niemi M, Backman JT (2006) Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 80:565-581.
38. Neuvonen PJ, Penttilä O, Roos M, Tirkkonen J (1976) Effect of long-term alcohol consumption on the half-life of tetracycline and doxycycline in man. Int J Clin Pharmacol Biopharm 14:303-307.
39. Nguyen-Khac E, Chatelain D, Tramier B, Decrombecque C, Robert B, Joly JP, Brevet M, Grignon P, Lion S, Le Page L, Dupas JL (2008) Assessment of asymptomatic liver fibrosis in alcoholic patients using fibroscan: prospective comparison with seven noninvasive laboratory tests. Aliment Pharmacol Ther 28:1188-1198.
40. Renton KW (2001) Alteration of drug biotransformation and elimination during infection and inflammation. Pharmacol Ther 92:147-163.
41. Rost KL, Brockmöller J, Esdorn F, Roots I (1995) Phenocopies of poor metabolizers of omeprazole caused by liver disease and drug treatment. J Hepatol 23:268-277.
42. Sandor P, Sellers EM, Dumbrell M, Khouw V (1981) Effect of short- and long-term alcohol use on phenytoin kinetics in chronic alcoholics. Clin Pharmacol Ther 30:390-397.
43. Sandrin L, Fourquet B, Hasquenoph JM, Yon S, Fournier C, Mal F, Christidis C, Ziol M, Poulet B, Kazemi F, Beaugrand M, Palau R (2003) Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 29:1705-1713.
44. Sellers EM, Busto U (1982) Benzodiazepines and ethanol: assessment of the effects and consequences of psychotropic drug interactions. J Clin Psychopharmacol 2:249-262.
45. Spray JW, Willett K, Chase D, Sindelar R, Connelly S (2007) Dosage adjustment for hepatic dysfunction based on Child-Pugh scores. Am J Health Syst Pharm 64:690, 692-693.
46. Verbeeck RK (2008) Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol 64:1147-1161.
47. Wasmuth HE, Tacke F, Trautwein C (2010) Chemokines in liver inflammation and fibrosis. Semin Liver Dis 30:215-225.
48. Weiss J, Herzog M, Haefeli WE (2011) Differential modulation of the expression of important drug metabolising enzymes and transporters by endothelin-1 receptor antagonists ambrisentan and bosentan in vitro. Eur J Pharmacol 660:298-304.
49. Yang H, Nie Y, Li Y, Wan YJ (2010) Histone modification-mediated CYP2E1 gene expression and apoptosis of HepG2 cells. Exp Biol Med (Maywood) 235:32-39.